A Phase 1b Study of Menin Inhibitor SNDX-5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged Disease.

This phase Ib trial tests the safety, side effects, and best dose of SNDX-5613 when given in combination with the standard chemotherapy treatment (daunorubicin and cytarabine) in treating patients with newly diagnosed acute myeloid leukemia that has changes in the NPM1 gene or MLL/KMT2A gene. SNDX-5613 blocks signals passed from one molecule to another inside cancer cells that are needed for cancer cell survival. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding SNDX-5613 to the standard chemotherapy treatment may be able to shrink or stabilize the cancer for longer than the standard chemotherapy treatment alone.

开始日期2024-11-10

申办/合作机构

National Cancer Institute

NCT06313437 / Not yet recruiting临床1期IIT

A Phase I Trial of Revumenib in Combination With 7+3 (7 Days of Cytarabine and 3 Days of Daunorubicin) + Midostaurin Induction Chemotherapy for the Frontline Treatment of NPM1 and FLT3 Mutated AML

This research is being conducted to determine a safe and effective dose of revumenib that can be given in combination with standard induction (initial therapy to induce a remission) + FLT3 targeted therapy (midostaurin) and a single cycle of post-remission therapy + FLT3 targeted therapy (midostaurin) to participants with newly diagnosed Nucleophosmin (NPM1) and FMS-like tyrosine kinase 3 (FLT3) mutated Acute Myeloid Leukemia (AML).
The names of the study drugs involved in this study are:
Revumenib (SNDX-5613) (a type of menin inhibitor)
Midostaurin (a type of multi-kinase including FLT3 inhibitor)
Cytarabine (a type of antineoplastic agent)
Daunorubicin (a type of antineoplastic agent)

开始日期2024-09-01

申办/合作机构

Dana-Farber Cancer Institute, Inc.

[+1]

NCT05554419 / Not yet recruiting临床2期IIT

Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial

This phase II MyeloMATCH treatment trial compares cytarabine versus (vs.) cytarabine and venetoclax vs. liposome-encapsulated daunorubicin-cytarabine and venetoclax vs. azacitidine and venetoclax for treating patients who have residual disease after treatment for acute myeloid leukemia (AML). Cytarabine is in a class of medications called antimetabolites. It works by slowing or stopping the growth of cancer cells in the body. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Liposome-encapsulated daunorubicin-cytarabine is a drug formulation that delivers daunorubicin and cytarabine in small spheres called liposomes, which may make the drugs safer or more effective. Azacitidine is a drug that interacts with DNA and leads to the activation of tumor suppressor genes, which are genes that help control cell growth. This study may help the study doctors find out if the different drug combinations are equally effective to the usual approach of cytarabine alone while requiring a shorter duration of treatment. To decide if they are better, the study doctors will be looking to see if the study drugs lead to a higher percentage of patients achieving a deeper remission compared to cytarabine alone.

开始日期2024-08-16

申办/合作机构

National Cancer Institute

100 项与阿糖胞苷相关的临床结果

登录后查看更多信息

100 项与阿糖胞苷相关的转化医学

登录后查看更多信息

100 项与阿糖胞苷相关的专利（医药）

登录后查看更多信息

24,354

项与阿糖胞苷相关的文献（医药）

2024-05-01·Food Chemistry

Enhanced stabilization of multifunctional phenolic acids-grafted chitin nanofibers for Pickering emulsions

Article

作者: Pang, Jie ; Xu, Jingting ; Duan, Mengxia ; Tong, Zhisheng ; Zhi, Zijian ; Li, Danjie ; Wu, Chunhua ; Huang, Chen ; Tong, Cailing

The objective of this study was to develop novel functional stabilizers for Pickering emulsions using phenolic acids-grafted chitin nanofibers (phenolic acids-g-ChNF), which were fabricated by grafting ferulic acid (FA), sinapic acid (SA) and caffeic acid (CA) onto ChNF via free radical-mediated method. The Fourier transform infrared spectrum and Proton nuclear magnetic resonance showed that graft copolymerization occurred between the amino groups of ChNF and the carbonyl of the phenolic acids. Further, it was revealed that CA-g-ChNF and SA-g-ChNF possessed stronger antioxidant and antibacterial properties than the original ChNF and FA-g-ChNF. Additionally, we applied phenolic acids-g-ChNF to develop Pickering emulsions and found that SA-g-ChNF- and CA-g-ChNF-stabilized emulsions displayed reduced droplet sizes compared to FA, the main reason for which was that SA and CA had a rather close bonding relationship with ChNF. Taken together, SA-g-ChNF and CA-g-ChNF as novel multi-functional particles can be employed for facilitating the stability of Pickering emulsions.

2024-05-01·Recent Patents on Anti-Cancer Drug Discovery

Chlorogenic Acid Inhibits Proliferation, Migration and Invasion of Pancreatic Cancer Cells via AKT/GSK-3β/β-catenin Signaling Pathway

Article

作者: Feng, Miao ; Bo, Jianing ; Tong, Jiale ; Yin, Lili ; Lin, Xiukun ; Chen, Xiaoliang ; Liu, Binyu

Background::

Chlorogenic acid (CA, United States Patent No. 10772340), a natural biologically active food ingredient, displays potent antitumor activity against a variety of cancer cells. However, the mechanism underlying its anticancer effect is not well elucidated.

Objective::

In the present study, we hope to dissect the mechanism underlying the anticancer effects of CA in pancreatic cancer cells.

Methods::

The cytotoxicity of CA in pancreatic cancer cells was determined by MTT assay. Flow cytometry was performed to evaluate the cells apoptosis, while a clonogenic assay was carried out to check the colony formation of cancer cells. Transwell assay was performed to assess the cells migration and invasion. The protein expression of AKT/GSK-3β/β-catenin signaling pathway was detected by Western Blot.

Results::

Our data indicated that CA inhibited the proliferation of PANC-28 and PANC-1 cells in a dose and time-dependent manner. CA was able to inhibit colony formation, migration, and invasion ability and trigger apoptosis in PANC-28 and PANC-1 cells. Further study showed that CA down-regulated the expression of AKT, p-AKT(Thr308), p-GSK-3β(Ser9), β-catenin, N-cadherin, and vimentin while enhancing the expression of cleaved-caspase 3 and cleaved-caspase 7 in PANC-28 and PANC-1 cells.

Conclusion::

Our study provides significant evidence that CA is able to inhibit the growth of pancreatic cancer via the AKT/GSK-3β/β-catenin signaling pathway.

2024-05-01·Value in Health Regional Issues

Economic Evaluation of Neoadjuvant Versus Adjuvant Chemotherapy in Cancer Treatment: A Systematic Review and Meta-Analysis

Article

作者: Huang, Chunji ; Huang, Guoqiong ; Xu, Rufu ; Wang, Na ; Li, Ying ; Wu, Dongdong

OBJECTIVES:

In the absence of evidence on whether neoadjuvant (NAC) or adjuvant chemotherapy (AC) is more beneficial for various tumor treatments, economic evaluation (EE) can assist medical decision making. There is limited evidence on their cost-effectiveness and their prospective evaluation is less likely in the future. Therefore, a systematic review and meta-analysis about EE for NAC versus AC in solid tumor help compare these therapies from various perspectives.

METHODS:

Various databases were searched for studies published from inception to 2021. This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and economic-specific guidelines. The data were pooled using a random effects model when possible.

RESULTS:

The retrieval identified 15 EE studies of NAC versus AC in 8 types of cancer. NAC is the dominant strategy for pancreatic, head and neck, rectal, prostate cancers and colorectal liver metastases. For ovarian cancer, NAC is cost-effective with a lower cost and higher or similar quality-adjusted life-year. There were no significant differences in cost and outcomes for lung cancer. For stage IV or high-risk patients with ovarian or prostate cancer, NAC was cost-effective but not for patients who were not high risk.

CONCLUSIONS:

The EEs results for NAC versus AC were inconsistent because of their different model structures, assumptions, cost inclusions, and a shortage of studies. There are multiple sources of heterogeneity across EEs evidence synthesis. More high-quality EE studies on NAC versus AC in initial cancer treatment are necessary.

229

项与阿糖胞苷相关的新闻（医药）

2024-04-18

·BioSpace

European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)

– Next-generation non-cardiotoxic anthracycline Annamycin with notable signs of clinical efficacy in AML in combination with Cytarabine achieves preliminary CRc rate of 60% in 2nd line AML subjects in a European clinical trial – There are approximately 160,000 people with AML worldwide – Annamycin continues to show no signs of cardiotoxicity (N=82 across multiple studies); Lower toxicity pro traditional intensive therapy – Annamycin is advancing towards pivotal AML study in 2024 and may qualify for an accelerated approval pathway HOUSTON, April 18, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to Annamycin for the treatment of AML. Annamycin is the Company's next-generation anthracycline that has been designed to be non-cardiotoxic (unlike currently prescribed anthracyclines) and has shown to be non-cardiotoxic in the 82 subjects treated in multiple studies in the U.S. and in Europe. Furthermore, Annamycin has recently shown in Moleculin's European clinical study for the treatment of AML using Annamycin in combination with Cytarabine (MB-106) a preliminary 60% composite complete response (CRc) rate in 2nd line subjects (N=10) and an overall interim CRc of 39% in all subjects (N=18), regardless of the prior number of therapies, in the European trial. Durability of the CRc's is developing. One subject has surpassed the one-year mark with a durable complete response. Recruitment in MB-106 has ended for 2nd line subjects while recruitment for 1st line and 3rd line subjects continue. Annamycin is currently in development for the treatment for AML and STS lung mets, and the Company believes the drug may have the potential to treat additional indications. "We are pleased to receive Orphan Drug Designation from the EMA for Annamycin, which further supports our ongoing efforts to advance this compelling next-generation anthracycline for the treatment of hard-to-treat cancers," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Combined with the Orphan Drug Designation we already have in the US and with the new composition of matter patent just awarded by the US Patent and Trademark Office with coverage through 2040, we believe the commercial exclusivity of Annamycin is now very well protected. We continue to be encouraged by the growing body of promising interim clinical data demonstrated by Annamycin. We remain focused on advancing our clinical and regulatory strategies toward our next phase of development, including the planned commencement of a pivotal registration study as a 2nd line therapy in AML before year end." The EMA grants orphan drug designation to drugs and biologics intended for the treatment, diagnosis or prevention of rare, life-threatening or chronically debilitating diseases or conditions that affect fewer than five in 10,000 people in the European Union. Orphan designation allows companies certain benefits, including reduced regulatory fees, clinical protocol assistance, research grants and up to 10 years of potential market exclusivity in the European Union if approved. Annamycin currently has Fast Track Status and Orphan Drug Designation from the U.S. Food and Drug Administration for the treatment of relapsed or refractory AML, in addition to Orphan Drug Designation for the treatment of STS lung mets. About Moleculin Biotech, Inc. Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. All interim and preliminary data discussed above is subject to change. Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. For more information about the Company, please visit and connect on Twitter, LinkedIn and Facebook. Forward-Looking Statements Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the commencement of a pivotal registration study of Annamycin as a 2nd line therapy in AML before year end. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission (SEC) and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events. Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 MBRX@jtcir.com Company Codes: NASDAQ-SMALL:MBRX

孤儿药快速通道临床2期加速审批临床结果

2024-04-18

·BioSpace

Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients

HOUSTON, April 18, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced completion of the second dose cohort of the dose escalation portion of its Phase 1/1b clinical trial of BP1002 evaluating the ability of BP1002 to treat refractory/relapsed acute myeloid leukemia (AML) patients, including venetoclax-resistant patients. “We are delighted to safely progress through the second, higher dose cohort to reach an important study milestone for the United States Food and Drug Administration (FDA) to review patient study data,” said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. “Enrollment rates have been good, and we look forward to advancing this study in even higher doses with the hope that we can sooner reach the combination therapy segment of our Phase 1/1b study with increased levels of BP1002 for the treatment of these vulnerable patients with few, if any, treatment options.” BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. The current standard of care for patients with AML not eligible for intensive chemotherapy is venetoclax, an oral Bcl-2 inhibitor that targets the BH3 domain of the Bcl-2 protein, in combination with a hypomethylating agent or with low-dose cytarabine. However, many patients become resistant to venetoclax treatment. A published study found that AML patients who had relapsed from frontline venetoclax-based treatment were refractory to salvage therapy and had a median survival of less than 3 months. By targeting Bcl-2 at the mRNA level rather than the protein, BP1002 may overcome and prevent some of the mechanisms of resistance that affect venetoclax treatment. Published preclinical Bio-Path studies have shown BP1002 to be a potent inhibitor against the Bcl-2 target, and we believe that its benign safety pro enable effective BP1002 combination therapy with approved agents, such as decitabine. The Phase 1/1b clinical trial is being conducted at several leading cancer centers in the United States, including the Weill Medical College of Cornell University, The University of Texas MD Anderson Cancer Center, Scripps Health, and The University of California at Los Angeles Cancer Center. Initially, the dose escalation portion of the clinical plan calls for a total of six evaluable patients to be treated with BP1002 monotherapy over two dose levels in a standard 3+3 design, with a starting dose of 20 mg/m2 and the second dose of 40 mg/m2. The testing of these two dose levels is now complete and the clinical trial will pause for a brief data review by the FDA, and then we expect that dose testing will continue at the next planned higher dose of 60 mg/m2. The approved treatment cycle is two doses per week over four weeks, resulting in eight doses administered over twenty-eight days. The Phase 1b portion of the study is expected to commence after completion of BP1002 monotherapy cohorts and will assess the safety and efficacy of BP1002 in combination with decitabine in refractory/relapsed AML patients. Gail J. Roboz, M.D., is the National Principal Investigator for the Phase 1/1b trial. Dr. Roboz is a professor of medicine and director of the Clinical and Translational Leukemia Program at the Weill Medical College of Cornell University and the New York-Presbyterian Hospital in New York City. Gary Schiller, M.D., The University of California at Los Angeles Cancer Center, Maro Ohanian, D.O., Department of Leukemia, University of Texas MD Anderson Cancer Center, and David Hermel, M.D., Scripps Health, are each serving as principal investigators. About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1/1b study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3. For more information, please visit the Company's website at . Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws. These statements are based on management's current expectations and accordingly are subject to uncertainty and changes in circumstances. Any express or implied statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including Bio-Path’s ability to raise needed additional capital on a timely basis in order for it to continue its operations, have success in the clinical development of its technologies, the timing of enrollment and release of data in such clinical studies, the accuracy of such data, limited patient populations of early stage clinical studies and the possibility that results from later stage clinical trials with much larger patient populations may not be consistent with earlier stage clinical trials, the maintenance of intellectual property rights, that patents relating to existing or future patent applications will be issued or that any issued patents will provide meaningful protection of our drug candidates, the impact, risks and uncertainties related to global pandemics, including the COVID-19 pandemic, and actions taken by governmental authorities or others in connection therewith, and such other risks which are identified in Bio-Path's most recent Annual Report on Form 10- K, in any subsequent quarterly reports on Form 10-Q and in other reports that Bio-Path files with the Securities and Exchange Commission from time to time. These documents are available on request from Bio-Path Holdings or at Bio-Path disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Contact Information: Investors Will O’Connor Stern Investor Relations 212-362-1200 will@sternir.com Doug Morris Investor Relations Bio-Path Holdings, Inc. 832-742-1369

临床1期临床2期寡核苷酸

2024-04-15

·信狐药迅

长春金赛抗IL-1β抗体金纳单抗首次报上市| 新受理（4.7-4.14）

本周药品注册受理数据，分门别类呈现，一目了然。(4.7-4.14）小编收到有些用户反应，不想收到咱们每周文章的推送提醒，而有些用户又特别需要这个提醒，在小编强烈要求下，我们给力的程序员终于实现了可以关闭提醒的功能，这个绝对全网独一家喔，不想收到提醒的，只要在信狐药迅对话框内回复关键词“拒收文章提醒”，那么就可以不受推送的打扰啦!新药上市申请药品名称企业注册分类受理号磷酸奥司他韦口腔崩解片北京星昊医药股份有限公司;北京星昊盈盛药业有限公司2.2CXHS2400027磷酸奥司他韦口腔崩解片北京星昊医药股份有限公司;北京星昊盈盛药业有限公司2.2CXHS2400026水合氯醛糖浆成都倍特得诺药业有限公司2.2CXHS2400025注射用金纳单抗长春金赛药业有限责任公司1CXSS2400040注射用金纳单抗长春金赛药业有限责任公司1CXSS2400039信迪利单抗注射液信达生物制药(苏州)有限公司2.2CXSS2400038新药临床申请药品名称企业注册分类受理号SGB-9768注射液苏州圣因生物医药有限公司1CXHL2400373PZH2113 胶囊漳州片仔癀药业股份有限公司1CXHL2400372PZH2113 胶囊漳州片仔癀药业股份有限公司1CXHL2400371JNJ-88998377口服片强生(中国)投资有限公司1CXHL2400370JNJ-88998377口服片强生(中国)投资有限公司1CXHL2400369JNJ-88998377口服片强生(中国)投资有限公司1CXHL2400368NS-136片纽欧申医药(上海)有限公司1CXHL2400366NS-136片纽欧申医药(上海)有限公司1CXHL2400365WD-890片浙江文达医药科技有限公司1CXHL2400361WD-890片浙江文达医药科技有限公司1CXHL2400360WD-890片浙江文达医药科技有限公司1CXHL2400359WD-890片浙江文达医药科技有限公司1CXHL2400358TQB3702片正大天晴药业集团股份有限公司1CXHL2400357GH21胶囊勤浩医药(苏州)有限公司1CXHL2400364GH21胶囊勤浩医药(苏州)有限公司1CXHL2400363D-1553片上海正大天晴医药科技开发有限公司1CXHL2400362YH001胶囊杭州禹泓医药科技有限公司1CXHL2400355YH001胶囊杭州禹泓医药科技有限公司1CXHL2400354注射用Y-3南京宁丹新药技术有限公司1CXHL2400350HMPL-500胶囊和记黄埔医药(上海)有限公司1CXHL2400349HMPL-500胶囊和记黄埔医药(上海)有限公司1CXHL2400348ZX-8177片南京征祥医药有限公司1CXHL2400347ZX-8177片南京征祥医药有限公司1CXHL2400346ACE-16229210片优领医药科技(上海)有限公司1CXHL2400345ACE-16229210片优领医药科技(上海)有限公司1CXHL2400344ACE-16229210片优领医药科技(上海)有限公司1CXHL2400343西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400342西奥罗尼胶囊深圳微芯生物科技股份有限公司1CXHL2400341RS-C1001片青岛睿森生物科技有限公司1CXHL2400340RS-C1001片青岛睿森生物科技有限公司1CXHL2400339KY386注射用浓溶液深圳开悦生命科技有限公司1CXHL2400338LN2227山东新时代药业有限公司2.2CXHL2400367BY029口服溶液北京柏雅联合药物研究所有限公司2.2CXHL2400356MEI-002注射液迈诺威(无锡)医药科技有限公司2.3CXHL2400353MEI-002注射液迈诺威(无锡)医药科技有限公司2.3CXHL2400352硝羟喹啉片江苏亚虹医药科技股份有限公司2.4CXHL2400351重组呼吸道合胞病毒疫苗(CHO细胞)成都华任康生物科技有限公司1.3CXSL2400228T3011疱疹病毒注射液苏州亦诺微医药科技有限公司1CXSL2400230T3011疱疹病毒注射液苏州亦诺微医药科技有限公司1CXSL2400229STSP-0902注射液舒泰神(北京)生物制药股份有限公司1CXSL2400227STSP-0902滴眼液舒泰神(北京)生物制药股份有限公司1CXSL2400226STSP-0902滴眼液舒泰神(北京)生物制药股份有限公司1CXSL2400225STSP-0902滴眼液舒泰神(北京)生物制药股份有限公司1CXSL2400224注射用LM-2417礼新医药科技(上海)有限公司1CXSL2400223VAY736注射液Novartis Pharma AG1JXSL2400070AK129注射液康方汇科(上海)生物有限公司1CXSL2400220IMC-002宜明凯尔生物医药技术(上海)有限公司1CXSL2400219RD118注射液南京驯鹿生物技术股份有限公司1CXSL2400218CM355北京天诺健成医药科技有限公司1CXSL2400217IMC-002宜明凯尔生物医药技术(上海)有限公司1CXSL2400216U87注射液上海优卡迪生物医药科技有限公司1CXSL2400222注射用SKB518四川科伦博泰生物医药股份有限公司1CXSL2400215注射用MK-2870默沙东研发(中国)有限公司1CXSL2400214注射用人脐带间充质干细胞艾尔普再生医学科技(深圳)有限公司1CXSL2400212泰它西普注射液荣昌生物制药(烟台)股份有限公司2.1;2.2CXSL2400213仿制药申请药品名称企业注册分类受理号硝普钠注射液湖南恒生制药股份有限公司3CYHS2401109西咪替丁注射液石家庄迪斯凯威医药科技有限公司3CYHS2401106水合氯醛灌肠剂宏越科技(湖州)有限公司3CYHS2401094依巴斯汀口服溶液合肥国药诺和药业有限公司3CYHS2401093左氧氟沙星注射液陕西博森生物制药股份集团有限公司3CYHS2401087盐酸普萘洛尔注射液北京布霖生物科技有限公司3CYHS2401085氟哌啶醇注射液上海理想制药有限公司3CYHS2401083吡格列酮二甲双胍片北京北陆药业股份有限公司3CYHS2401078氯化钾颗粒成都通德药业有限公司3CYHS2401070琥珀酸亚铁片北京斯利安药业有限公司3CYHS2401069盐酸肾上腺素注射液嘉实(湖南)医药科技有限公司3CYHS2401066米诺地尔搽剂杭州端本医药科技有限公司3CYHS2401064米诺地尔搽剂杭州端本医药科技有限公司3CYHS2401063草酸艾司西酞普兰口服溶液安徽四环科宝制药有限公司3CYHS2401061聚乙二醇钠钾散雅安迅康药业有限公司3CYHS2401059间苯三酚口腔崩解片浙江赛默制药有限公司3CYHS2401057复方聚乙二醇(3350)电解质散成都倍特药业股份有限公司3CYHS2401055复方聚乙二醇(3350)电解质散成都倍特药业股份有限公司3CYHS2401054复合磷酸氢钾注射液浙江赛默制药有限公司3CYHS2401053注射用水溶性维生素内蒙古白医制药股份有限公司3CYHS2401073醋酸钙片河北华晨药业集团有限公司3CYHS2401040二羟丙茶碱注射液湖北欣泽霏药业有限公司3CYHS2401037硫酸沙丁胺醇注射液海南皇隆制药股份有限公司3CYHS2401033帕米膦酸二钠注射液广州艾奇西新药研究有限公司3CYHS2401043甲硫酸新斯的明注射液广州市联瑞制药有限公司3CYHS2401025注射用奥氮平齐鲁制药有限公司3CYHS2401024腺苷钴胺胶囊华北制药股份有限公司3CYHS2401022阿仑膦酸钠口服溶液山东朗诺制药有限公司3CYHS2401018复合磷酸氢钾注射液华夏生生药业(北京)有限公司3CYHS2401015盐酸肾上腺素注射液湖南海誓生物医药有限公司3CYHS2401032腺苷钴胺胶囊杭州沐源生物医药科技有限公司3CYHS2401029硫酸吗啡缓释片威海路坦制药有限公司4CYHS2401098利培酮口腔崩解片北京星昊医药股份有限公司4CYHS2401111利培酮口腔崩解片北京星昊医药股份有限公司4CYHS2401110硫酸特布他林雾化吸入用溶液吉林敖东药业集团延吉股份有限公司4CYHS2401108阿达帕林凝胶江苏知原药业股份有限公司4CYHS2401107注射用丁二磺酸腺苷蛋氨酸石家庄四药有限公司4CYHS2401105普拉洛芬滴眼液广州大光制药有限公司4CYHS2401104利格列汀片甘李药业山东有限公司4CYHS2401103硫酸镁钠钾口服用浓溶液山东如至生物医药科技有限公司4CYHS2401102头孢托仑匹酯颗粒海南葫芦娃药业集团股份有限公司4CYHS2401101头孢托仑匹酯颗粒海南葫芦娃药业集团股份有限公司4CYHS2401100培哚普利氨氯地平片(III)武汉熙瑞医药科技有限公司4CYHS2401099达格列净二甲双胍缓释片(III)北京伟林恒昌医药科技有限公司4CYHS2401097达格列净二甲双胍缓释片(I)北京伟林恒昌医药科技有限公司4CYHS2401096注射用阿糖胞苷合肥亿帆生物制药有限公司4CYHS2401092注射用阿糖胞苷合肥亿帆生物制药有限公司4CYHS2401091帕拉米韦氯化钠注射液山东齐都药业有限公司4CYHS2401090帕拉米韦氯化钠注射液山东齐都药业有限公司4CYHS2401089美沙拉秦肠溶片浙江贝得药业有限公司4CYHS2401088碘普罗胺注射液上海司太立制药有限公司4CYHS2401095厄贝沙坦氢氯噻嗪片江西施美药业股份有限公司4CYHS2401079西甲硅油乳剂河南中杰药业有限公司4CYHS2401084恩格列净片烟台鲁银药业有限公司4CYHS2401086利丙双卡因乳膏湖北人福成田药业有限公司4CYHS2401082注射用厄他培南广东万泰科创药业有限公司4CYHS2401081利丙双卡因乳膏深圳市泰力生物医药有限公司4CYHS2401080硫酸镁钠钾口服用浓溶液珠海横琴国研医药科技有限公司4CYHS2401077布洛芬混悬液湖南状元制药有限公司4CYHS2401072布洛芬混悬液湖南状元制药有限公司4CYHS2401071罗替高汀贴片北京泰德制药股份有限公司4CYHS2401068左氧氟沙星片浙江昂利康制药股份有限公司4CYHS2401067伊布替尼胶囊昆山龙灯瑞迪制药有限公司4CYHS2401065注射用硫酸艾沙康唑四川宏明博思药业有限公司4CYHS2401062聚乙二醇钠钾散雅安迅康药业有限公司4CYHS2401060注射用硫酸艾沙康唑海南通用三洋药业有限公司4CYHS2401052甲苯磺酸艾多沙班片浙江诺得药业有限公司4CYHS2401051甲苯磺酸艾多沙班片浙江诺得药业有限公司4CYHS2401050艾考糊精腹膜透析液成都诺和晟鸿生物制药有限公司4CYHS2401049米拉贝隆缓释片南京易亨制药有限公司4CYHS2401048盐酸乌拉地尔注射液山东达冠医药科技有限公司4CYHS2401076盐酸乌拉地尔注射液山东达冠医药科技有限公司4CYHS2401075精氨酸布洛芬颗粒石家庄四药有限公司4CYHS2401074多替拉韦钠片上海迪赛诺医药集团股份有限公司4CYHS2401058硫酸镁钠钾口服用浓溶液浙江凯润药业股份有限公司4CYHS2401056盐酸决奈达隆片齐鲁制药有限公司4CYHS2401042左氧氟沙星片湖南状元制药有限公司4CYHS2401041复方电解质注射液(II)辰欣药业股份有限公司4CYHS2401039复方电解质注射液(II)辰欣药业股份有限公司4CYHS2401038普拉替尼胶囊基石药业(苏州)有限公司4CYHS2401036氨甲环酸注射液海南爱科制药有限公司4CYHS2401035氨甲环酸注射液海南爱科制药有限公司4CYHS2401034硫酸氨基葡萄糖胶囊天津天士力圣特制药有限公司4CYHS2401047米拉贝隆缓释片山东朗诺制药有限公司4CYHS2401046盐酸尼卡地平注射液海南爱科制药有限公司4CYHS2401045富马酸伏诺拉生片裕松源药业有限公司4CYHS2401044比拉斯汀片江苏悦兴药业有限公司4CYHS2401027依非米替片(I)安徽贝克生物制药有限公司4CYHS2401026乳酸钠林格注射液华夏生生药业(北京)有限公司4CYHS2401021哌柏西利胶囊北京双鹭药业股份有限公司4CYHS2401020哌柏西利胶囊北京双鹭药业股份有限公司4CYHS2401019氧河南众益气体有限公司4CYHS2401016卡贝缩宫素注射液长春圣金诺生物制药有限公司4CYHS2401031注射用伏立康唑北京吉洛华制药有限公司4CYHS2401030注射用丁二磺酸腺苷蛋氨酸福建省宝诺医药研发有限公司4CYHS2401028富马酸福莫特罗吸入溶液成都海德康药业有限公司4CYHS2401023普拉洛芬滴眼液山东辰欣佛都药业股份有限公司4CYHS2401017Sabin株脊髓灰质炎灭活疫苗(Vero细胞)北京民海生物科技有限公司3.3CXSS2400041氟轻松氢醌维A酸乳膏杭州中美华东制药有限公司3CYHL2400075甘露醇山梨醇注射液南京恩泰医药科技有限公司3CYHL2400074利多卡因丁卡因乳膏江苏盈科生物制药有限公司3CYHL2400070氟比洛芬凝胶贴膏北京阳光诺和药物研究股份有限公司4CYHL2400076洛索洛芬钠凝胶贴膏海南赛立克药业有限公司4CYHL2400073氟比洛芬凝胶贴膏海南赛立克药业有限公司4CYHL2400072氮䓬斯汀氟替卡松鼻喷雾剂山东京卫制药有限公司4CYHL2400071QL2108注射液齐鲁制药有限公司3.3CXSL2400221进口申请药品名称企业注册分类受理号注射用双羟萘酸帕瑞肽微球Recordati Rare Diseases5.1JXHS2400032注射用双羟萘酸帕瑞肽微球Recordati Rare Diseases5.1JXHS2400031注射用双羟萘酸帕瑞肽微球Recordati Rare Diseases5.1JXHS2400030注射用牛肺表面活性剂Lyomark Pharma GmbH5.1JXHS2400029注射用牛肺表面活性剂Lyomark Pharma GmbH5.1JXHS2400028注射用罗特西普Celgene Corporation3.1JXSS2400036注射用罗特西普Celgene Corporation3.1JXSS2400035泊沙康唑口服混悬液Deva Holding A.S5.2JYHS2400015BI 1819479 片Boehringer Ingelheim International GmbH1JXHL2400089BI 1819479 片Boehringer Ingelheim International GmbH1JXHL2400088Capivasertib片AstraZeneca AB2.4JXHL2400087Capivasertib片AstraZeneca AB2.4JXHL2400086Amycretin片Novo Nordisk A/S1JXSL2400073Amycretin片Novo Nordisk A/S1JXSL2400072Amycretin片Novo Nordisk A/S1JXSL2400071BSI-992注射液Biosion USA, Inc.1JXSL2400069BAY 3018250Bayer AG1JXSL2400068帕博利珠单抗注射液Merck Sharp & Dohme LLC2.2JXSL2400074Ravulizumab注射液Alexion Pharmaceuticals Inc.3.1JXSL2400075中药相关申请药品名称企业注册分类受理号益气消瘤颗粒广东方盛融大药业有限公司1.1CXZL2400019不包含原料药、医用氧、注射用水、氯化钠或葡萄糖注射液等申请，不包含再注册、一次性进口、技术转移、复审申请。

申请上市

100 项与阿糖胞苷相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00168	阿糖胞苷	L01BC01	DB00987

研发状态

适应症	最高研发状态	国家/地区	公司
急性髓性白血病	批准上市	日本更多	Nippon Shinyaku Co., Ltd. 更多
套细胞淋巴瘤	临床2期	美国更多	Roswell Park Comprehensive Cancer Center 更多
脑膜癌病	撤市	欧盟更多	Pacira Ltd. 更多
弥漫性大B细胞淋巴瘤	终止	德国更多	Celgene Corp. 更多
难治性侵袭性非霍奇金淋巴瘤	无进展	-	NCIC Clinical Trials Group 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02135874 (CTgov)	临床2期	复发性混合表型急性白血病 \| 急性双系白血病 \| 急性双表型白血病 ... 更多	16	Clofarabine+sorafenib+dexamethasone+Rituximab+Vincristine+Cytarabine+Idarubicin	衊選網遞製獵膚築繭積(齋積壓齋網製積齋繭醖) = 鏇簾廠積餘鑰蓋醖鹹壓願艱衊廠襯蓋淵鹽築觸 (襯糧鑰獵艱鹽廠壓願積, 齋糧簾築壓艱鏇獵網築 ~ 積醖壓廠製廠襯願鹽窪) 更多	-	2024-03-19
NCT02611492 (GRAAPH-2014, Pubmed)	临床3期	费城染色体阳性急性淋巴细胞白血病巩固	156	Nilotinib + Cytarabine	築壓蓋獵衊膚艱淵簾鹹(廠鑰選廠繭觸顧構鬱糧) = 構壓遞選願餘夢餘選簾積鹹憲齋願簾築壓簾壓 (醖廠憲膚簾觸獵憲製糧 ) 更多	不佳	2024-03-07
				Nilotinib	築壓蓋獵衊膚艱淵簾鹹(廠鑰選廠繭觸顧構鬱糧) = 鹹蓋壓範淵範糧襯窪構積鹹憲齋願簾築壓簾壓 (醖廠憲膚簾觸獵憲製糧 ) 更多
NCT01829503 (Phase 2 study of epigenetic priming with decitabine followed by cytarabine for acute myeloid leukemia in older patients, Pubmed)	临床2期	急性髓性白血病一线	-	Decitabine 20 mg/m2	糧鹽鬱鏇顧築簾餘衊淵(積蓋遞鹹繭膚鹽餘廠鏇) = 廠鑰壓網醖淵膚簾齋壓淵鬱範艱願繭選淵繭蓋 (繭夢積簾構鏇選窪衊憲 ) 更多	积极	2024-01-22
				Cytarabine 100 mg/m2	膚淵夢願選鏇築鹽鹽襯(艱顧選構醖壓構鬱醖觸) = 夢衊鬱簾顧艱繭夢鑰積壓蓋夢鏇鏇廠醖艱襯鹹 (衊繭鹹願構衊夢鹽廠繭 )
NCT02441803 (CTgov)	临床2期	急性髓性白血病	11	Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Decitabine+cytarabine+Idarubicin (Matched Sibling Donor Group)	醖願獵鑰積鹽夢窪淵遞(淵鏇鹽壓齋願壓顧鏇願) = 夢醖鏇選齋淵繭壓鏇衊糧顧衊構遞範淵壓憲選 (鹹鬱淵繭選製餘鏇選積, 壓衊簾製築廠鏇壓選糧 ~ 衊淵齋憲夢積獵夢願顧) 更多	-	2024-01-17
				Stem Cell Infusion+Clofarabine+Fludarabine+Busulfan+Cyclophosphamide+Decitabine+Tacrolimus+mycophenolate mofetil+cytarabine+Idarubicin (Haploidentical Donor Group)	醖願獵鑰積鹽夢窪淵遞(淵鏇鹽壓齋願壓顧鏇願) = 齋壓範餘糧鏇衊繭夢鹹糧顧衊構遞範淵壓憲選 (鹹鬱淵繭選製餘鏇選積, 餘積夢艱憲鹽淵鏇鏇網 ~ 製鏇鹹遞鑰鹽築繭鏇夢) 更多
ISRCTN78449203 (Pubmed)	临床3期	急性髓性白血病 NPM1 \| FLT3	-	Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin with Gemtuzumab Ozogamicin	醖齋鏇膚鹽築繭淵顧艱(壓壓築壓餘遞淵鹽鏇鑰) = 衊鏇遞積觸鬱獵餘簾鹹願積鑰憲獵蓋簾簾鑰選 (鏇遞餘鬱糧壓製築遞築 ) 更多	-	2024-01-12
				Daunorubicin and Ara-C with Gemtuzumab Ozogamicin	醖齋鏇膚鹽築繭淵顧艱(壓壓築壓餘遞淵鹽鏇鑰) = 構壓鑰製鑰蓋糧鹹艱範願積鑰憲獵蓋簾簾鑰選 (鏇遞餘鬱糧壓製築遞築 ) 更多
NOPHO-DBH AML2012 (ASH2023)	临床3期	未经治疗的小儿急性非淋巴细胞白血病	306	AD(x)E	夢構構窪鹽獵廠淵遞襯(觸構鹽襯淵壓繭淵築夢) = 願艱齋淵鑰壓鹽簾構鹹襯繭顧夢鹹積鏇衊夢蓋 (觸鏇廠醖積遞壓衊齋鏇 ) 更多	-	2023-12-11
				FLAD(x)	夢構構窪鹽獵廠淵遞襯(觸構鹽襯淵壓繭淵築夢) = 齋窪獵鬱繭艱獵範憲願襯繭顧夢鹹積鏇衊夢蓋 (觸鏇廠醖積遞壓衊齋鏇 ) 更多
NCT03586609 (ASH2023)	临床2期	急性髓性白血病巩固	123	CLAD-LDAC-Ven	鏇壓遞糧網衊簾壓醖壓(網網鑰簾憲窪簾廠網壓) = 簾鏇憲觸鏇積窪築構艱積構糧夢構鏇構艱醖鹹 (糧獵築簾蓋築選獵鬱獵 ) 更多	-	2023-12-11
BIG-1 (ASH2023)	临床1/2期	急性髓性白血病巩固	15	Venetoclax + IDAC	艱夢齋憲觸繭鹹觸顧繭(繭淵觸製蓋鹹簾繭遞選) = 餘遞構鬱窪壓製獵壓繭遞衊選廠餘壓憲艱積窪 (糧襯襯壓糧築範獵構餘 ) 更多	-	2023-12-11
ASH2023	N/A	原发性中枢神经系统淋巴瘤巩固	72	Methotrexate-Temozolomide-Rituximab Induction	膚窪鏇選製鬱鹹憲壓鹽(選網顧齋選齋選蓋憲艱) = 淵獵範願鬱鬱餘範鏇觸範襯積齋鹹糧廠膚壓鹹 (夢衊壓製衊觸鬱觸鬱觸 ) 更多	-	2023-12-11
ASH2023	临床2期	前体B细胞急性淋巴细胞白血病	75	Hyper-CVADHyper-CVADHyper-CVADHyper-CVADHyper-CVADHyper-CVAD	製艱齋糧憲構襯鹹鬱醖(窪窪選襯淵醖鹹觸膚顧) = 蓋積範積構醖憲窪壓鏇壓顧窪範繭糧鑰願鬱繭 (鹽選蓋觸築淵範鏇構鏇 ) 更多	-	2023-12-11
				Hyper-CVADHyper-CVADHyper-CVADHyper-CVADHyper-CVADHyper-CVAD + Inotuzumab Ozogamicin	製艱齋糧憲構襯鹹鬱醖(窪窪選襯淵醖鹹觸膚顧) = 糧積膚餘襯願壓憲醖積壓顧窪範繭糧鑰願鬱繭 (鹽選蓋觸築淵範鏇構鏇 ) 更多